XTX Topco Ltd Buys 20,532 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Key Points

• XTX Topco Ltd increased its position in Ultragenyx Pharmaceutical Inc. by 182.5%, acquiring a total of 31,780 shares worth approximately $1.15 million.
• During the first quarter, various institutional investors, including GAMMA Investing LLC and ANTIPODES PARTNERS Ltd, made notable investments in Ultragenyx, contributing to a total institutional ownership of 97.67%.
• Ultragenyx recently reported a negative EPS of ($1.57) for the quarter, missing estimates, while revenues grew 28.0% year-over-year but still fell short of analyst expectations.

XTX Topco Ltd boosted its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 182.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 31,780 shares of the biopharmaceutical company's stock after acquiring an additional 20,532 shares during the quarter. XTX Topco Ltd's holdings in Ultragenyx Pharmaceutical were worth $1,151,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 323 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical during the 1st quarter worth approximately $57,000. GF Fund Management CO. LTD. purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $82,000. Finally, Quarry LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $84,000. Institutional investors own 97.67% of the company's stock.

Insider Activity

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.50% of the company's stock.

Wall Street Analysts Forecast Growth

RARE has been the subject of a number of recent research reports. Wedbush reduced their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Wells Fargo & Company decreased their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. William Blair started coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target on the stock. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a research note on Monday, July 28th. Finally, Morgan Stanley lowered their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $83.08.

Ultragenyx Pharmaceutical Trading Up 0.1%

Shares of RARE stock traded up $0.02 during mid-day trading on Monday, reaching $28.46. The stock had a trading volume of 1,651,473 shares, compared to its average volume of 3,302,327. The firm has a market capitalization of $2.69 billion, a PE ratio of -4.84 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37. The stock's 50-day moving average price is $33.84 and its two-hundred day moving average price is $37.07.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative return on equity of 186.49% and a negative net margin of 93.04%. Ultragenyx Pharmaceutical's quarterly revenue was up 28.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.03) earnings per share. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.